SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (38)11/26/1996 8:31:00 AM
From: TheSlowLane   of 675
 
I don't claim to understand medical technology. Or, as Bones would say "Damn it Jim, I'm a technologist not a opthamologist". When I spoke to my friend, who IS an opthamologist, his first reaction was the same as yours, this development will take years to hit the market. He, nor I were claiming that this treatment was the same as Cerestat, we don't know enough about it, although he knows a lot more than I do. He did say that if a drug is fundamentally the same as one that has already gone through the clinical trials and been approve that the approval process for the new drug can be expedited. Again, I am just passing along info (or misinformation) I myself am not intimately familiar with the FDA approval process.
I had not heard that Cerestat is hallucinogenic. Does this mean that there may be a secondary market for it (in leisure/entertainment)? Ha ha, just kidding...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News